WUND Healing Biotherapeutics (WUND), which has purchased the U.S. and Canadian rights to market Zhittya’s entire wound healing drug portfolio.
Zhittya’s main corporate function will be overseeing the clinical development of different formulations of FGF-1 for unique medical indications. Through USA FDA-authorized clinical studies, it will seek to advance these drugs up to and through the US FDA approval process. Zhittya will not market any of its approved drug products but will work with its marketing partners in defined territories to sell and distribute the approved drugs worldwide. To date, Zhittya has completed marketing agreements with the following partners in their respective specified territories:
These partners include the following:
South East Asia - Regenerative Medicine of South East Asia (RSEA)
Latin America - Regenerative Medicine of Latin America (RMLA)
Greater China - Regenerative Medicine of China- (RMCN)
India - Regenerative Medicine of India (RMIN)
Korea - Regenerative Medicine of Korea (RMKO)
Japan - Regenerative Medicine of Japan (RMJP)
ANZ - Regenerative Medicine of ANZ (RANZ)
which acquired the rights to market Zhittya’s wound healing pharmaceuticals in Europe.
Derma Healing BioPharmaceuticals Inc. (DERMA),
In addition to these 3 publicly announced agreements, Zhittya is currently negotiating seven additional marketing partnerships which will allow its drugs to be sold and distributed by its partners throughout the rest of the world, including the regions of China, South-East Asia, Latin America, India, Korea, Japan and Australia/New Zealand.
Jeldeyah Healing BioPharmaceuticals Inc. (JBIO), to market Zhittya’s wound healing drugs in the Middle East and North Africa.